All In Biotech

Drug Trial Radar · NCT00522951

SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study

Multi-center, Randomized, Controlled, Single-blind, Intra-individual Comparisons of 2 Dose of Gadobutrol 1.0 Molar and Gadoteridol (ProHance) Crossover Studies With Corresponding Blinded Image Evaluation Following Multiple Injections of 0.1 mmol/kg bw of Gadobutrol and Gadoteridol in Patients With Known or Suspected Brain Metastasis

Last checked: Nov 19, 2026Latest source record: Aug 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 165 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

165

Actual

Start

Aug 2007

Primary completion

Aug 2008

Study completion Aug 2008

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Aug 30, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Single (participant)
Primary purpose
Diagnostic
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is conducted to compare the contrast effect and safety of SH L562BB with ProHance, which has already been approved as a pharmaceutical product of similar indication.

Conditions

  • Brain Metastases

Interventions

  • Gadobutrol (Gadavist, Gadovist, BAY86-4875)Drug

    Gadobutrol enhanced MRI (first injection of gadobutrol 0.1 mmol/kg bw, corresponding to a dose of 0.1 mmol/kg bw)

  • Gadobutrol (Gadavist, Gadovist, BAY86-4875)Drug

    Gadobutrol enhanced MRI (second injection of gadobutrol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw)

  • ProHanceDrug

    ProHance enhanced MRI (two injections of gadoteridol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Lesions Detected by Blinded Readers (BR) and InvestigatorTime frame: one day

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Fukuoka, Japan

  • Site not named

    Osaka, Japan

  • Site not named

    Nagoya, Aichi-ken, Japan

  • Site not named

    Matsuyama, Ehime, Japan

  • Site not named

    Kitakyushu, Fukuoka, Japan

  • Site not named

    Sapporo, Hokkaido, Japan

  • Site not named

    Kobe, Hyōgo, Japan

  • Site not named

    Sagamihara, Kanagawa, Japan

  • Site not named

    Yokohama, Kanagawa, Japan

  • Site not named

    Habikino, Osaka, Japan

  • Site not named

    Habikino, Osaka, Japan

  • Site not named

    Sayama, Osaka, Japan

  • Site not named

    Hamamatsu, Shizuoka, Japan

  • Site not named

    Sunto, Shizuoka, Japan

  • Site not named

    Bunkyo-ku, Tokyo, Japan

  • Site not named

    Bunkyo-ku, Tokyo, Japan

  • Site not named

    Chuo-ku, Tokyo, Japan

  • Site not named

    Mitaka, Tokyo, Japan

  • Site not named

    Shinagawa-ku, Tokyo, Japan

  • Site not named

    Yonago, Tottori, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.